Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

Apoptosis is a form of non-lytic programmed cell death that is important as a driver of normal development, for cell population maintenance ... SOD1 to bind and block an anti-apoptotic protein, B cell ...

Recursion Pharmaceuticals RXRX announced that it has dosed the first patient in its early-stage study of investigational ...

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

“It really is very important. . . . You now have [a priority designation] that is very clearly for tissue and cell [therapies],” Beth Roxland ... potentially life-saving therapies.” The RMAT pathway ...